Skip to main content

Table 1 Absolute intra-group differences between T1 (week 14) and T2 (week 26) together with mean relative difference for each of the variables in each group evaluated.

From: Intra-articular vs. systemic administration of etanercept in antigen-induced arthritis in the temporomandibular joint. Part II: mandibular growth

Variable

Group

Absolute mean T1 value

Absolute mean T2 value

Absolute mean difference T2-T1

Relative mean difference from T1 to T2 (%)

Standard deviation (%)

Statistical significance for growth between T1 and T2

Angle 1

A

155.3

156.6

1.3

0.84

1.7

n.s.

 

B

155.8

156.4

0.6

0.4

2.9

n.s.

 

C

153.9

154.1

0.2

0.1

1.6

n.s.

Angle 2

A

136.1

133.8

-2.3

-1.7

2.2

*

 

B

136.2

135.1

-1.1

-0.7

5.2

n.s.

 

C

138.7

137.4

-1.3

-1

2.2

n.s.

Angle 3

A

108.3

109.3

1

0.9

1.2

*

 

B

107.3

108.6

1.3

1.3

1.5

*

 

C

108.3

109.6

1.3

1.2

1.3

*

Sagittal (mm)

TML

A

61.5

66.6

5.1

8.3

2.1

*

(Cm-ImpB)

B

60.7

65.8

5.1

8.4

1.9

*

 

C

60.8

66.2

5.4

8.8

1.8

*

ML1

A

36.2

38.1

1.9

5

2.4

*

(Go-ImpB)

B

36.5

38.2

1.7

4.6

2.5

*

 

C

35.9

37.6

2

5

2.1

*

ML2

A

55.6

59.7

4.1

7.3

1.7

*

(Ar1-ImpB)

B

55.3

59.0

3.7

7.2

2.2

*

 

C

54.8

58.7

3.9

7.2

2.6

*

ML3

A

58.6

63.3

4.7

8

1.8

*

(Ar2-ImpB)

B

58.6

63.1

4.5

7.7

0.9

*

 

C

58.3

62.8

4.5

7.7

1.4

*

ID

A

15.1

15.5

0.4

3

6.2

n.s.

(impA-impB)

B

14.8

15.1

0.3

2.7

5.8

n.s.

 

C

14.1

14.0

-0.1

-1.3

8.1

n.s.

Vertical (mm)

TPMH

A

44.2

48.8

4.6

10.4

1.5

*

(CmR-GoR)

B

43.3

47.9

4.6

10.8

1.9

*

 

C

43.5

49.0

5.5

12.6

1.7

*

CMH1

A

21.4

23.7

2.3

10.7

1.1

*

(CmR-Ar1)

B

21.1

23.2

2.1

9.9

3.5

*

 

C

21.3

23.6

2.3

10.8

2.6

*

CMH2

A

22.3

24.3

2

8.9

2.0

*

(CmR-Ar2)

B

22.2

24.3

2.1

9.4

2.9

*

 

C

22.1

24.4

3.3

10.0

2.3

*

RH1

A

27.4

30.3

2.9

10.7

2.5

*

(Ar1-GoR)

B

26.8

29.7

2.9

11.0

2.3

*

 

C

26.8

29.9

3.1

11.6

3.5

*

RH2

A

29.5

32.9

3.4

11.9

3.4

*

(Ar2-GoR)

B

28.9

32.5

3.6

12.3

2.5

*

 

C

29.2

32.9

3.7

12.7

2.7

*

MBH1

A

12.5

13.8

1.3

10.4

13.9

*

(IncRIL)

B

12.7

13.4

0.7

6.91

16.3

*

 

C

12.3

13.6

1.3

12.1

12.4

*

MBH2

A

18.3

20.5

2.2

12.2

3.7

*

(MolRIL)

B

17.9

19.8

1.9

11.1

2.9

*

 

C

17.7

20.2

2.5

14.1

3.9

*

DAH

A

7.5

8.2

0.7

8.9

10.6

*

(MolRML)

B

7.3

7.9

0.6

8.8

14.4

n.s.

 

C

7.7

8.7

1

12.6

8.4

*

ANH

A

2.9

3.4

0.5

17.2

18.2

*

(IncRML)

B

2.9

3.4

0.5

17.2

26.9

*

 

C

2.6

2.9

0.3

11.5

35.3

*

Transverse (mm)

GD

A

28.1

29.6

1.5

5.5

2.8

*

(GoR-GoL)

B

29.0

30.1

1.1

3.9

2.0

*

 

C

28.4

29.9

1.5

5.5

2.5

*

CD

A

33.4

34.7

1.3

4.3

2.4

*

(CmR-CmL)

B

32.5

33.9

1.4

4.5

2.2

*

 

C

33.2

34.4

1.2

3.7

1.3

*

  1. *P < 0.05
  2. Angles (degrees)
  3. Groups: A) placebo, B) IA etanercept, C) systemic etanercept. See figures 3, 4 and 5 for a description of the variables.